Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. - Steinmetz,H.AT.; Schulz,A.; Staib,P.; Scheid,C.; Glasmacher,A.; Neufang,A.; Franklin,J.; Tesch,H.; Diehl,V.; Wickramanayake,P.D. (Ann Hematol, 1999)